Although recombinase polymerase amplification (RPA) has many advantages for the detection of pathogenic nucleic acids in point-of-care applications, RPA has not yet been applied for has not yet been implemented to quantify sample concentration using a standard curve. Here we describe a real-time RPA assay with an internal positive control and an algorithm that analyzes the real-time fluorescence data to quantify HIV-1 DNA. We show that DNA concentration and the onset of detectable amplification are correlated by an exponential standard curve. In a set of experiments in which the standard curve and algorithm were used to analyze and quantify additional DNA samples, the algorithm predicted an average concentration within one order of magnitude of the correct concentration for all HIV-1 DNA concentrations tested. These results suggest that qRPA may serve as a powerful tool for quantifying nucleic acids and may be adapted for use in single-sample point-of-care diagnostic systems.
INTRODUCTION
For sensitive and specific diagnosis of many infectious diseases, real-time polymerase chain reaction (PCR) is widely considered to be the gold standard method. In clinical settings, real-time PCR is used for both detection and quantification of pathogenic nucleic acids. For example, HIV-1 proviral DNA is detected for pediatric diagnosis, while HIV-1 viral RNA is quantified to monitor treatment efficacy and disease progression. 1, 2 In areas where the infectious disease burden is highest, however, real-time PCR is often infeasible because of the requirement for expensive thermal cycling equipment, technical expertise, and other resources that may be unavailable in poor settings.
To address this problem, isothermal amplification platforms have been developed that rapidly amplify nucleic acids to detectable levels at a single temperature, alleviating the need for thermal cycling equipment. 3 Recombinase polymerase amplification (RPA) offers significant advantages over other isothermal amplification techniques for point-of-care applications: it requires a lower amplification temperature, is tolerant to impure samples, amplifies targets to detectable levels within minutes, and uses lyophilized enzymes to enable storage and transport at room temperature. 4, 5 For these reasons, a number of recent reports have proposed RPA-based strategies for the detection of pathogens. [6] [7] [8] [9] [10] Although some papers demonstrate a relationship between nucleic acid concentration and onset of amplification, 10, 11 to the best of our knowledge, RPA has not yet been implemented to quantify sample concentration using a standard curve. Moreover, the accuracy with which samples can be quantified with real-time RPA has not yet been characterized.
In this study, we explore the feasibility of developing a quantitative RPA assay using real-time fluorescence monitoring. With the ultimate goal of developing an assay for use with a point-of-care
reader, we designed an assay to enable quantification of HIV-1 DNA in a single sample by referencing a standard curve determined previously (e.g. during calibration). This proof-of-concept quantitative RPA (qRPA) assay detects HIV-1 DNA and an internal positive control (IPC) sequence, which are both amplified by the HIV-1 primers and detected using probe sequences conjugated to different fluorophores ( Figure 1 ). Using a benchtop real-time PCR machine, RPA was performed to determine the correlation between the HIV-1 DNA target concentration and fluorescence intensity during amplification. Next, the IPC was generated and similarly assessed. Finally, both HIV-1 DNA and the IPC were amplified within the same reaction to generate data for the development, training, and validation of a custom algorithm for DNA quantification. RPA reactions were assembled without magnesium acetate, avoiding direct exposure to light, and placed in a cold block cooled to 4 °C. Magnesium acetate, which is necessary for enzymatic activity, was Table S1 ). The PCR products, which served as the IPC, consisted of a C. parvum sequence flanked by the HIV-1 primer sequences (shown schematically in Figure 1 ). Generation of the 435 bp IPC was verified by gel electrophoresis, after which the DNA was extracted, purified, and diluted.
METHODS

Real
Quantification algorithm for analysis of real-time data. Raw fluorescence data were analyzed using a custom MATLAB script. To score a sample as positive or negative, the difference Δ sample between the maximum and minimum fluorescence was determined for each sample. The average difference Δ background and standard deviation σ background were calculated for all no-target control samples. A sample was considered positive if Δ sample was more than z* σ background above Δ background . Values for z varied from one to five to determine the effect of this parameter on the sensitivity and accuracy of the algorithm.
Each sample was scored as negative or positive for both HIV-1 and the IPC. Samples that scored as negative for both HIV-1 and the IPC were considered invalid and removed from further analysis.
For each sample identified as positive for HIV-1, the raw fluorescence intensity from the HEX channel, which corresponded to amplification of the HIV-1 sequence, was smoothed with a five point running average. The slope was estimated at each time point by calculating the difference in fluorescence intensity between each time point and the previous time point. A slope threshold S was chosen to estimate the time at which detectable amplification began. The value of S was chosen such that the greatest slope of the no-target control samples was slightly less than S. The same value for S was used for both the training and the validation datasets. Preliminary analysis showed that minor changes in S did not significantly affect the sensitivity, specificity, or dynamic range of the algorithm (data not shown). The time T at which detectable amplification began was defined as the first time point at which the slope was greater than S. T was found for all positive samples from five experiments. T average was plotted for each concentration tested, and regression analysis was performed to construct a standard curve relating T to target concentration. To evaluate the accuracy of the algorithm, the concentration was predicted for samples from five additional experiments by calculating T and using the equation for the standard curve.
RESULTS
The generation of IPC DNA was verified by the presence of a 435 bp band on an agarose gel after electrophoresis ( Figure S1 ). Preliminary RPA experiments detecting HIV-1 DNA and IPC DNA in separate reactions demonstrated that T, the time at which detectable amplification begins, increases with decreasing DNA concentration, suggesting that quantification of DNA with RPA is feasible.
Five experiments were then performed to characterize the performance of the qRPA assay in which both HIV-1 DNA and the IPC were amplified. Raw fluorescence data for a typical experiment are shown in Figure 2 , where HIV-1 DNA was detected using a HEX-labeled probe (Figure 2A) , and the IPC was detected using a FAM-labeled probe ( Figure 2B ). None of samples were scored as negative for both the DNA concentration and T, demonstrated that an exponential fit yielded a higher correlation coefficient than first-and second-order polynomial fits. An exponential standard curve derived using data from the five experiments is plotted in Figure 3 , in which samples were considered positive if Δ sample was more than one σ background above Δ background (z = 1). Standard curves using integer values of z from one to five had similar equations and correlation coefficients (data not shown).
The accuracy and precision of the algorithm in predicting the HIV-1 DNA concentration from the raw fluorescence data was evaluated with five additional experiments, using the exponential standard curves calculated for the training data. As for the training data, all samples were classified as valid. Table   1 shows the performance of the algorithm when z = 1, using the standard curve shown in Figure 3 
DISCUSSION
These results provide proof-of-concept to support the use of RPA for accurate quantification of nucleic acid concentration with a standard curve determined previously. For example, when combined with a reverse transcriptase step, the qRPA assay described here may be adapted to determine HIV-1 RNA viral load. As most commercially available viral load assays have a limit of detection of at least 3 log 10 (HIV-1 RNA copies/mL), and patient viral loads may exceed 6 log 10 (copies/mL), a clinically useful HIV-1 RNA viral load test must be able to quantify plasma viremia over at least four orders of magnitude. 13 A viral load test should also have a precision of at least 0.5 log 10 (copies/mL), which is considered to be a significant change in viral load. 14 Finally, a viral load test must be especially accurate at low viral loads because therapeutic failure due to drug resistance is characterized by viral loads between 500-1000 (copies/mL), 2 and successful suppression of viral replication is indicated by viral loads less than 200
(copies/mL). 14 This qRPA assay can quantify DNA concentrations over four orders of magnitude with a precision greater than 0.5 log 10 (copies per reaction) and is most accurate at low DNA concentrations.
These results suggest that a qRPA assay similar to the one described here may have the potential to accurately identify these clinical benchmarks.
This qRPA assay may also be adapted for quantification of other targets by modifying the assay and algorithm parameters. For example, the criteria for identifying positive samples can greatly affect the sensitivity and linear dynamic range of the algorithm. As shown in Figure 3 and Table 1 , predicted DNA concentrations are more accurate for lower concentrations than for higher concentrations when z = 1.
Alternatively, using higher values for z decreases the sensitivity for lower concentrations but increases the accuracy for higher concentrations. Figure 4 demonstrates how changing z alters the sensitivity at low concentrations, the accuracy across detectable concentrations, and the precision of predicted concentrations. In addition to altering the algorithm parameters, the assay could potentially be optimized for greater accuracy by collecting fluorescence data more frequently or decreasing the reaction rate by either decreasing the concentration of magnesium acetate in the reaction or amplifying at a lower temperature.
This assay was designed for use with an inexpensive, point-of-care fluorescence reader, such as the commercially available Twista portable real-time fluorometer (TwistDx, Ltd., Cambridge, United Kingdom) or the ESEQuant Tube Scanner (Qiagen, Valencia, USA). In order to adapt this assay for use in the field, however, several factors must be considered. Because RPA lacks true 'cycles' to limit the rate of DNA amplification, and amplicons can be generated in a matter of minutes, the rate of amplification must be precisely controlled. A consistent amplification rate may be achieved by using the same reagent concentrations for each experiment and by precisely controlling the temperature during each reaction.
Reagent consistency was achieved by using whole enzyme pellets as supplied by the manufacturer, and by using the same primer aliquots for both the experiments used to build the standard curve and the experiments using the standard curve to predict concentration of samples. The temperature was controlled within ±0.2⁰C by using a bench-top thermal cycler according to the manufacturer's specifications (BioRad CFX96 Touch™ Real-Time PCR Detection System). Deviations from these specifications and their influence on consistent amplification should be explored in future studies. In addition, reaction components must be protected from heat and light to prevent enzyme activity loss and photobleaching of probes. To ensure accurate results, reactions must be started immediately before fluorescence monitoring, which may be accomplished by adding magnesium acetate immediately before data collection begins. If these conditions are achieved, qRPA may serve as a powerful tool for quantifying nucleic acids in single samples at the point of care. Thus, the algorithm can be tuned depending on clinical needs. and to predict the concentration of samples for five additional experiments (z = 1). All concentrations are given in units of log 10 (copies per reaction).
